Recently, Sarah Glaven, Assistant Director of the White House Office of Science and Technology Policy (OSTP), gave a speech at Boston Biotechnology Week, emphasizing that Biden's support policies for domestic biomanufacturing will not be affected by the upcoming election results. Glaven stated that this policy has received broad support from both parties, and whether Harris or Trump is elected, Executive Order 14081 will remain in effect.
This order aims to promote a government wide approach to biotechnology and biomanufacturing to advance scientific development, reduce commercialization barriers, accelerate product launch, reduce biological risks, and protect economic competitiveness and national security.
Sarah Glaven mentioned the reward program led by the US Department of Defense to accelerate the development of biotechnology projects, which supports 25 biotechnology companies to expand their technology projects.
This initiative is part of the Biden administration's push for a government wide approach to biotechnology and biomanufacturing, aimed at accelerating the commercialization of scientific achievements and reducing the time and cost of product launches.
Glaven also mentioned the establishment of the National Bioeconomy Commission to address supply chain dependence issues, which is dedicated to addressing logistics barriers, high costs, and supply chain dependence, particularly in relation to China.
The establishment of this committee demonstrates the US government's determination to reduce external dependence and enhance domestic supply chains in the field of bioeconomy.
Cross party cooperation, supporting the fields of biotechnology and biomanufacturing. Glaven emphasized that issues in biotechnology and biomanufacturing have always been the focus of bipartisan cooperation, and this cooperation will not change with political uncertainty.
She reviewed the focus on biotechnology and biomanufacturing during the Obama administration, as well as the Trump administration's summit focused on the bioeconomy in 2019, all of which demonstrate the tradition of bipartisan cooperation in this field.
The role of the federal government: creating a favorable business environment. Glaven emphasized the role of the federal government in supporting the business environment and becoming a partner in the bioeconomy.
She mentioned that the federal government wants to ensure that its policies and procurement practices support a favorable business environment and consider the full impact of regulatory environments to promote the development of biotechnology and biomanufacturing industries.
